Gilead Sciences (GILD.US) acquires PepStar's oral inflammation drug project for $1.275 billion in cash, strengthening its inflammatory bowel disease pipeline.
智通财经2026/10/23 00:35Show original
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!
A welcome pack worth 6200 USDT for new users! Sign up now!
Zhihu Finance APP has learned that Gilead Sciences (GILD.US) announced on Thursday it will acquire PepStar Therapeutics’ oral inflammation drug program for an upfront cash payment of $1.275 billion, which includes an experimental gut disease therapy. This deal comes after Gilead’s experimental oral drug emvistegrast for chronic intestinal disease reported positive mid-stage results on Monday, adding another inflammatory bowel disease (IBD) candidate to its portfolio. Gilead stated it believes HCXT-2001 has potential either as a standalone development or in combination with other pipeline projects.
0
0
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!
You may also like
Amazon reportedly to acquire AI startup Decart for $7.5 billion
智通财经•2026/11/21 17:56


Wealth Managers Overtake Hedge Funds as Largest Bitcoin ETP Holders
Coinedition•2026/11/21 11:35

Crypto prices
MoreBitcoin
BTC
$60,361.07
+3.53%
Ethereum
ETH
$1,684.46
+5.18%
Tether USDt
USDT
$0.9977
-0.01%
BNB
BNB
$548.26
+2.95%
USDC
USDC
$0.9999
+0.00%
XRP
XRP
$0.9312
+5.25%
Solana
SOL
$70.45
+4.78%
TRON
TRX
$0.3049
+1.39%
Hyperliquid
HYPE
$61.55
+2.07%
Zcash
ZEC
$792.66
+8.96%
How to buy BTC
Bitget lists BTC – Buy or sell BTC quickly on Bitget!
Trade now
Become a trader now?A welcome pack worth 6200 USDT for new users!
Sign up now